$1.08
+0.03 (+2.86%)
Open$1.08
Previous Close$1.05
Day High$1.08
Day Low$1.05
52W High$2.64
52W Low$0.50
Volume—
Avg Volume203.1K
Market Cap45.53M
P/E Ratio0.85
EPS$1.23
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+925.0% upside
Current
$1.08
$1.08
Target
$11.07
$11.07
$6.75
$11.07 avg
$12.78
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.51M | 19.87M | 7.77M |
| Net Income | 54.34M | 77.64M | 1.80M |
| Profit Margin | 434.2% | 412.5% | 23.2% |
| EBITDA | -27,367,063 | -41,274,344 | 2.38M |
| Free Cash Flow | — | — | 1.78M |
| Rev Growth | -37.0% | -37.0% | +3.8% |
| Debt/Equity | — | — | 0.84 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |